Phibro Animal Health stock
PAHCNASDAQPhibro Animal Health Corporation, HealthcareISIN US71742Q1067
58Score 58 out of 100, Neutral
Price and trend
33 / 100
Price history
−22% in one yearThe chart shows daily closes over 13 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 14% below it.
Since June 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 38).
The price is 40% below its 52-week high. Largest decline in 13 years: 82% (August 2018 to November 2023).
Chart figures for advanced users
- SMA 50$36.80
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$41.07
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)38
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$28.52
- The lowest closing price of the last twelve months.
- Resistance$59.58
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Phibro Animal Health Corporation belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $1.44B, is number 61 of 78 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $1.52B (up 17.1% year on year) and earnings of $99.72M (up 106.6%).
- For fiscal 2027, analysts expect on average revenue of $1.58B (up 4.1%) and adjusted earnings per share of $3.49 (up 8.6%).
Show more
- MEQIRI Score 58 out of 100 (Neutral): rank 308 of 714 in Healthcare, median 53.
- The P/E is 14.1 (Drug Manufacturers (Specialty & Generic) median 19.3, own median of recent years 21.6).
- Our model puts fair value at $44.90, with the price 22% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 66
- Reliable dividendNo dividend cut for 12 years.Capital allocation 59
- Modestly valuedP/E 14.1, Drug Manufacturers (Specialty & Generic) median 19.3, own median 21.6.Valuation 76
Weaknesses
- High debtDebt 1.89 times equity (latest quarter), Drug Manufacturers (Specialty & Generic) median 0.49.Stability 48
- Volatile share priceVolatility 55% a year over the last 12 months.Stability 48
Its standout strength is valuation, while momentum and technical analysis hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- price far below its 52-week high
Valuation
Valuation signal
Modestly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $32.07 and expensive above $74.83 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $41.29 (cash-flow model) and $48.50 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $41.27, at 7.8% it would be $50.35.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 10.1% on the twelve months before. Revenue has grown solidly since 2007, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 34%, operating 13%, net 7%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 3 Feb 2027in 83 days
- Last reported
- 4 Nov 2026EPS reported $0.79 (expected $0.78)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $3.49−0.4%
- Revenue
- $1.58B+0.2%
- Earnings per share
- $3.86+0.5%
- Revenue
- $1.63B+0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +4.4%First guidance for fiscal 2027, taking a prudent view of known uncertainties such as Brazil, with no comparison to earlier guidance.
“With that context, our fiscal 2027 guidance reflects confidence in the underlying business while taking a prudent view of known uncertainties.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Aug 2026 (fiscal Q4 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $317,700 in total.
- Corcoran E ThomasPurchase
29 May 2026, Board
- Shares
- 10,000
- Price
- $31.77
- Value
- $317,700
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Phibro Animal Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 58
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- SupernusSUPN $1.72B62
- ANI PharmaceuticalsANIP $1.63B61
- PolyPeptide GroupPPGN.SW $1.61B42
- Pacira BioSciencesPCRX $1.46B58
- Cronos GroupCRON $1.26B61
- BioGaiaBIOG-B.ST $1.25B75
- Amphastar PharmaceuticalsAMPH $1.22B76
- VetoquinolVETO.PA $1.13B77
ETFs that hold Phibro Animal Health
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.05% | 0.35% | €1.21B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.05% | 0.30% | €2.28B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.04% | 0.43% | €2.48B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.35% | €434.1M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Mar 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.